Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 124 articles:
HTML format



Single Articles


    June 2020
  1. BASARANOGLU M, Kapsigay M, Kunduz E
    Increased neuroendocrine tumours, but small colorectal cancer incidence in patients with inflammatory bowel disease treated by mesalazine.
    Eur J Gastroenterol Hepatol. 2020;32:763.
    PubMed    


    April 2020
  2. LI Q, Zhang T, Ding X, Xiang L, et al
    Enhancing patient adherence to fecal microbiota transplantation maintains the long-term clinical effects in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2020 Apr 10. doi: 10.1097/MEG.0000000000001725.
    PubMed     Abstract available


  3. BARDASI G, Romagnoli A, Foschini MP, Mantovani A, et al
    Pyostomatitis vegetans in a pediatric patient with ulcerative colitis: case report of a rare pediatric inflammatory bowel disease extraintestinal manifestation and review of the literature.
    Eur J Gastroenterol Hepatol. 2020 Apr 10. doi: 10.1097/MEG.0000000000001723.
    PubMed     Abstract available


  4. BERTANI L, Mumolo MG, Tapete G, Albano E, et al
    Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment.
    Eur J Gastroenterol Hepatol. 2020 Apr 8. doi: 10.1097/MEG.0000000000001731.
    PubMed     Abstract available


  5. HANAEI S, Sanati G, Sadr M, Salmanroghani R, et al
    DNA methylation of SOCS3 in intestinal biopsy and peripheral blood samples of Iranian patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2020;32:540-541.
    PubMed    


    March 2020
  6. LI X, Sun L, Chen L, Xu Y, et al
    Upregulation of microRNA-219-5p relieves ulcerative colitis through balancing the differentiation of Treg/Th17 cells.
    Eur J Gastroenterol Hepatol. 2020 Mar 13. doi: 10.1097/MEG.0000000000001712.
    PubMed     Abstract available


    February 2020
  7. PHILLIPS J, Preskey R, Penfold C, Gordon F, et al
    Liver steatosis is a risk factor for hepatotoxicity in inflammatory bowel disease patients treated with azathioprine.
    Eur J Gastroenterol Hepatol. 2020 Feb 21. doi: 10.1097/MEG.0000000000001683.
    PubMed     Abstract available


  8. KARAIVAZOGLOU K, Konstantakis C, Tourkochristou E, Assimakopoulos SF, et al
    Non-alcoholic fatty liver disease in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2020 Feb 8. doi: 10.1097/MEG.0000000000001679.
    PubMed     Abstract available


    January 2020
  9. MANTAKA A, Tsoukali E, Fragkaki M, Karmiris K, et al
    The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020 Jan 8. doi: 10.1097/MEG.0000000000001674.
    PubMed     Abstract available


    December 2019
  10. ALGETHMI W, Baumann C, Alnajjar W, Sroji A, et al
    Environmental exposures and the risk of inflammatory bowel disease: a case-control study from Saudi Arabia.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001619.
    PubMed     Abstract available


  11. KUMAR A, Lukin DJ
    Incident heart failure is a predictor of adverse outcomes in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001648.
    PubMed     Abstract available


  12. NERI B, Stingone C, Romeo S, Sena G, et al
    Inflammatory bowel disease versus Chlamydia trachomatis infection: a case report and revision of the literature.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001605.
    PubMed     Abstract available


  13. SWEENEY L, Moss-Morris R, Czuber-Dochan W, Murrells T, et al
    Developing a better biopsychosocial understanding of pain in inflammatory bowel disease: a cross-sectional study.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001615.
    PubMed     Abstract available


  14. SCHOEPFER A, Vavricka SR, Brungger B, Blozik E, et al
    Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland.
    Eur J Gastroenterol Hepatol. 2019 Dec 9. doi: 10.1097/MEG.0000000000001616.
    PubMed     Abstract available


    November 2019
  15. KAWAKAMI A, Choong LM, Tanaka M, Kunisaki R, et al
    Validation of the English version of the difficulty of life scale for patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2019 Nov 7. doi: 10.1097/MEG.0000000000001595.
    PubMed     Abstract available


  16. VIOLA A, Monterubbianesi R, Scalisi G, Furfaro F, et al
    Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study.
    Eur J Gastroenterol Hepatol. 2019;31:1361-1369.
    PubMed     Abstract available


  17. NAFTALI T, Bar-Lev Schleider L, Sklerovsky Benjaminov F, Lish I, et al
    Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects.
    Eur J Gastroenterol Hepatol. 2019;31:1376-1381.
    PubMed     Abstract available


    October 2019
  18. LANGHORST J, Koch AK, Voiss P, Dobos GJ, et al
    Distinct patterns of short-chain fatty acids during flare in patients with ulcerative colitis under treatment with mesalamine or a herbal combination of myrrh, chamomile flowers, and coffee charcoal: secondary analysis of a randomized controlled trial
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001582.
    PubMed     Abstract available


  19. KIM S, Park S, Kang Y, Koh H, et al
    Combining faecal calprotectin and sigmoidoscopy can predict mucosal healing in paediatric ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2019 Oct 22. doi: 10.1097/MEG.0000000000001550.
    PubMed     Abstract available


  20. QUIROZ-CRUZ S, Posada-Reyes B, Alatorre-Garcia T, Del Real-Calzada CM, et al
    Genetic polymorphisms present in IL10, IL23R, NOD2, and ATG16L1 associated with susceptibility to inflammatory bowel disease in Mexican population.
    Eur J Gastroenterol Hepatol. 2019 Oct 22. doi: 10.1097/MEG.0000000000001540.
    PubMed     Abstract available


  21. MOSES J, Lambert-Jenkins K, Momotaz H, Sattar A, et al
    Time to antibody detection and associated factors for presence of anti-drug antibodies in pediatric inflammatory bowel disease patients treated with anti-TNF therapy.
    Eur J Gastroenterol Hepatol. 2019;31:1228-1233.
    PubMed     Abstract available


  22. GROCHENIG HP, Waldhor T, Haas T, Wenzl H, et al
    Prevalence and indicators of use of complementary and alternative medicine in Austrian patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2019;31:1211-1219.
    PubMed     Abstract available


  23. KOURKOULIS P, Kapizioni C, Michalopoulos G, Andreou NP, et al
    Novel potential biomarkers for the diagnosis and monitoring of patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2019;31:1173-1183.
    PubMed     Abstract available


    September 2019
  24. SCHOENEFUSS F, Hoffmann P
    Serum gamma-globulin and albumin concentrations predict secondary loss of response to anti-TNFalpha in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2019 Sep 16. doi: 10.1097/MEG.0000000000001493.
    PubMed     Abstract available


  25. FEUERSTEIN JD, Curran T, Alvares D, Alosilla M, et al
    Surgery for ulcerative colitis in geriatric patients is safe with similar risk to younger patients.
    Eur J Gastroenterol Hepatol. 2019 Sep 11. doi: 10.1097/MEG.0000000000001529.
    PubMed     Abstract available


    August 2019
  26. PETRYSZYN P, Staniak A, Wolosianska A, Ekk-Cierniakowski P, et al
    Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis.
    Eur J Gastroenterol Hepatol. 2019 Aug 27. doi: 10.1097/MEG.0000000000001509.
    PubMed     Abstract available


    June 2019
  27. SOUSA M, Ladeira I, Ponte A, Fernandes C, et al
    Screening for latent tuberculosis in patients with inflammatory bowel disease under antitumor necrosis factor: data from a Portuguese center.
    Eur J Gastroenterol Hepatol. 2019 Jun 14. doi: 10.1097/MEG.0000000000001469.
    PubMed     Abstract available


  28. SHI H, Feng Y, Jiang J, Zhao J, et al
    Correlations between the serum bilirubin level and ulcerative colitis: a case-control study.
    Eur J Gastroenterol Hepatol. 2019 Jun 12. doi: 10.1097/MEG.0000000000001466.
    PubMed     Abstract available


  29. WU S, He C, Tang TY, Li YQ, et al
    A review on co-existent Epstein-Barr virus-induced complications in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2019 Jun 12. doi: 10.1097/MEG.0000000000001474.
    PubMed     Abstract available


    May 2019
  30. BRUNA-BARRANCO I, Lue A, Gargallo-Puyuelo CJ, Arroyo MT, et al
    Young age and tobacco use are predictors of lower medication adherence in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2019 May 16. doi: 10.1097/MEG.0000000000001436.
    PubMed     Abstract available


  31. LARSEN L, Jess T, Drewes AM, Dige A, et al
    Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment.
    Eur J Gastroenterol Hepatol. 2019 May 14. doi: 10.1097/MEG.0000000000001440.
    PubMed     Abstract available


  32. BOKEMEYER B, Luehr D, Helwig U, Maaser C, et al
    Small bowel capsule endoscopy in ulcerative colitis: the capcolitis study: a prospective observational study.
    Eur J Gastroenterol Hepatol. 2019 May 6. doi: 10.1097/MEG.0000000000001410.
    PubMed     Abstract available


    April 2019
  33. VIAZIS N, Pontas C, Karmiris K, Dimas I, et al
    Prevalence of Clostridium difficile infection among hospitalized inflammatory bowel disease patients in Greece.
    Eur J Gastroenterol Hepatol. 2019 Apr 9. doi: 10.1097/MEG.0000000000001414.
    PubMed     Abstract available


  34. AKYUZ F, Cavus B, Iliaz R, Soyer OM, et al
    Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
    Eur J Gastroenterol Hepatol. 2019 Apr 5. doi: 10.1097/MEG.0000000000001403.
    PubMed     Abstract available


  35. HALD M, Carlsen K, Nordgaard-Lassen I, Wewer V, et al
    Challenges and obstacles in the transition process through the eyes of the gastroenterologist.
    Eur J Gastroenterol Hepatol. 2019;31:486-493.
    PubMed     Abstract available


    March 2019
  36. DAVIS R, McParland P, Dodd S, Storey D, et al
    Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2019 Mar 6. doi: 10.1097/MEG.0000000000001395.
    PubMed     Abstract available


  37. ARIEIRA C, Monteiro S, Xavier S, Dias de Castro F, et al
    Hepatic steatosis and patients with inflammatory bowel disease: when transient elastography makes the difference.
    Eur J Gastroenterol Hepatol. 2019 Mar 4. doi: 10.1097/MEG.0000000000001319.
    PubMed     Abstract available


  38. MOENS A, Verstockt B, Machiels K, Bossuyt P, et al
    Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades.
    Eur J Gastroenterol Hepatol. 2019 Mar 4. doi: 10.1097/MEG.0000000000001394.
    PubMed     Abstract available


    January 2019
  39. LIEFFERINCKX C, Minsart C, Cremer A, Amininejad L, et al
    Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.
    Eur J Gastroenterol Hepatol. 2019 Jan 21. doi: 10.1097/MEG.0000000000001356.
    PubMed     Abstract available


  40. ESSMANN J, Keil C, Unruh O, Otte A, et al
    Fecal calprotectin is significantly linked to azathioprine metabolite concentrations in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2019;31:99-108.
    PubMed     Abstract available


    December 2018
  41. ORFANOUDAKI E, Gazouli M, Foteinogiannopoulou K, Theodoraki E, et al
    Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Eur J Gastroenterol Hepatol. 2018 Dec 12. doi: 10.1097/MEG.0000000000001332.
    PubMed     Abstract available


  42. BHOYRUL B, Hilmy M, Lyon C
    Crohn's disease of the penis and scrotum: a prospective study.
    Eur J Gastroenterol Hepatol. 2018;30:1528-1529.
    PubMed    


  43. VERDEJO C, Hervias D, Roncero O, Arias A, et al
    Fecal calprotectin is not superior to serum C-reactive protein or the Harvey-Bradshaw index in predicting postoperative endoscopic recurrence in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2018;30:1521-1527.
    PubMed     Abstract available


    October 2018
  44. MOLENDIJK I, van der Meulen-de Jong AE, Verspaget HW, Veenendaal RA, et al
    Standardization of mesenchymal stromal cell therapy for perianal fistulizing Crohn's disease.
    Eur J Gastroenterol Hepatol. 2018;30:1148-1154.
    PubMed     Abstract available


  45. AALTONEN G, Keranen I, Carpelan-Holmstrom M, Lepisto A, et al
    Risk factors for anastomotic recurrence after primary ileocaecal resection in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2018;30:1143-1147.
    PubMed     Abstract available


  46. BOHN THOMSEN S, Kiszka-Kanowitz M, Theede K, Gluud LL, et al
    Optimized thiopurine therapy before withdrawal of anti-tumour necrosis factor-alpha in patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2018;30:1155-1158.
    PubMed     Abstract available


    September 2018
  47. JUNG ES, Petersen BS, Mayr G, Cheon JH, et al
    Compound heterozygous mutations in IL10RA combined with a complement factor properdin mutation in infantile-onset inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2018 Sep 7. doi: 10.1097/MEG.0000000000001247.
    PubMed     Abstract available


  48. MOSLI M, Alfaer S, Almalaki T, Albeshry A, et al
    Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes?
    Eur J Gastroenterol Hepatol. 2018 Sep 7. doi: 10.1097/MEG.0000000000001249.
    PubMed     Abstract available


  49. COENEN S, Schmickler MN, Staes D, Wieme F, et al
    Investing in workability of patients with inflammatory bowel disease: results of a pilot project Activ84worK (Activate for work).
    Eur J Gastroenterol Hepatol. 2018 Sep 5. doi: 10.1097/MEG.0000000000001257.
    PubMed     Abstract available


  50. BRENNAN GT, Ha I, Hogan C, Nguyen E, et al
    Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn's disease patients: a meta-analysis.
    Eur J Gastroenterol Hepatol. 2018;30:997-1002.
    PubMed     Abstract available


    August 2018
  51. WALLDORF J, Twarz M, Schober C, Michl P, et al
    High frequency of secondary, but not primary ocular manifestations of inflammatory bowel disease in patients treated at a tertiary care center.
    Eur J Gastroenterol Hepatol. 2018 Aug 24. doi: 10.1097/MEG.0000000000001248.
    PubMed     Abstract available


  52. ZAMMIT SC, Ellul P, Girardin G, Valpiani D, et al
    Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study.
    Eur J Gastroenterol Hepatol. 2018 Aug 21. doi: 10.1097/MEG.0000000000001238.
    PubMed     Abstract available


  53. MITSELOS IV, Katsanos KH, Tatsioni A, Skamnelos A, et al
    Association of clinical and inflammatory markers with small bowel capsule endoscopy findings in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2018;30:861-867.
    PubMed     Abstract available


    July 2018
  54. SIMSEK M, Seinen ML, de Boer NKH
    Nodular regenerative hyperplasia in inflammatory bowel disease patients with allopurinol-thiopurine cotherapy.
    Eur J Gastroenterol Hepatol. 2018 Jul 30. doi: 10.1097/MEG.0000000000001218.
    PubMed    


  55. DE CHAMBRUN GP, Nachury M, Funakoshi N, Gerard R, et al
    Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis.
    Eur J Gastroenterol Hepatol. 2018 Jul 26. doi: 10.1097/MEG.0000000000001223.
    PubMed     Abstract available


  56. NAHON S, Ramtohul T, Paupard T, Belhassan M, et al
    Evolution in clinical presentation of inflammatory bowel disease over time at diagnosis: a multicenter cohort study.
    Eur J Gastroenterol Hepatol. 2018 Jul 12. doi: 10.1097/MEG.0000000000001201.
    PubMed     Abstract available


  57. GUILCHER K, Fournier N, Schoepfer A, Schibli S, et al
    Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland.
    Eur J Gastroenterol Hepatol. 2018 Jul 5. doi: 10.1097/MEG.0000000000001197.
    PubMed     Abstract available


  58. LO B, Julsgaard M, Vester-Andersen MK, Vind I, et al
    Disease activity, steroid use and extraintestinal manifestation are associated with increased disability in patients with inflammatory bowel disease using the inflammatory bowel disease disability index: a cross-sectional multicentre cohort study.
    Eur J Gastroenterol Hepatol. 2018 Jul 3. doi: 10.1097/MEG.0000000000001199.
    PubMed     Abstract available


  59. KRIDIN K, Comaneshter D, Cohen AD
    Short article: Crohn's disease and pemphigus: is there an association?: a population-based study.
    Eur J Gastroenterol Hepatol. 2018;30:727-729.
    PubMed     Abstract available


    June 2018
  60. REZAPOUR M, Galoosian A, Liu B, Bhuket T, et al
    Clostridium difficile co-infection in inflammatory bowel disease is associated with significantly increased in-hospital mortality.
    Eur J Gastroenterol Hepatol. 2018 Jun 11. doi: 10.1097/MEG.0000000000001185.
    PubMed     Abstract available


  61. O'CONNELL J, Rowan C, Stack R, Harkin G, et al
    Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2018 Jun 6. doi: 10.1097/MEG.0000000000001177.
    PubMed     Abstract available


    May 2018
  62. DERIKX LAAP, de Jong ME, Hoentjen F
    Recommendations on rectal surveillance for colorectal cancer after subtotal colectomy in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2018 May 17. doi: 10.1097/MEG.0000000000001171.
    PubMed     Abstract available


  63. SCHOEPFER A, Vavricka SR, Brungger B, Reich O, et al
    Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.
    Eur J Gastroenterol Hepatol. 2018 May 11. doi: 10.1097/MEG.0000000000001160.
    PubMed     Abstract available


  64. EGEA-VALENZUELA J, Gonzalez Suarez B, Sierra Bernal C, Juanmartinena Fernandez JF, et al
    Development and validation of a scoring index to predict the presence of lesions in capsule endoscopy in patients with suspected Crohn's disease of the small bowel: a Spanish multicenter study.
    Eur J Gastroenterol Hepatol. 2018;30:499-505.
    PubMed     Abstract available


  65. BOSSUYT P, Debeuckelaere C, Ferrante M, Vanbeckevoort D, et al
    The operative risk and natural history after the diagnosis of ileal penetrating Crohn's disease.
    Eur J Gastroenterol Hepatol. 2018;30:539-545.
    PubMed     Abstract available


    April 2018
  66. CHAN W, Lynch N, Bampton P, Chang J, et al
    Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1097/MEG.0000000000001150.
    PubMed     Abstract available


  67. LAPUMNUAYPOL K, Kanjanahattakij N, Pisarcik D, Thongprayoon C, et al
    Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis.
    Eur J Gastroenterol Hepatol. 2018 Apr 24. doi: 10.1097/MEG.0000000000001144.
    PubMed     Abstract available


  68. MERAL M, Bengi G, Kayahan H, Akarsu M, et al
    Is ileocecal valve intubation essential for routine colonoscopic examination?
    Eur J Gastroenterol Hepatol. 2018;30:432-437.
    PubMed     Abstract available


  69. PERNAT DROBEZ C, Repnik K, Gorenjak M, Ferkolj I, et al
    DNA polymorphisms predict time to progression from uncomplicated to complicated Crohn's disease.
    Eur J Gastroenterol Hepatol. 2018;30:447-455.
    PubMed     Abstract available


  70. HOLKO P, Kawalec P, Stawowczyk E
    Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012-2014: an analysis of nationwide databases.
    Eur J Gastroenterol Hepatol. 2018;30:456-464.
    PubMed     Abstract available


    March 2018
  71. HOEKSTRA J, van Roon AHC, Bekkering FC, van Tilburg AJP, et al
    Decision making and outcome of pregnancies in female patients with inflammatory bowel disease: findings from a community-based practice.
    Eur J Gastroenterol Hepatol. 2018 Mar 14. doi: 10.1097/MEG.0000000000001117.
    PubMed     Abstract available


  72. BINKHORST L, Sobels A, Stuyt R, Westerman EM, et al
    Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2018 Mar 13. doi: 10.1097/MEG.0000000000001113.
    PubMed     Abstract available


    February 2018
  73. LOBO JL, Garcia-Fuertes JA, Trujillo-Santos J, Merah A, et al
    Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2018 Feb 16. doi: 10.1097/MEG.0000000000001084.
    PubMed     Abstract available


  74. NOBILE S, Grand RJ, Pappa HM
    Risk factors for low bone mineral density in pediatric inflammatory bowel disease: the positive role of physical activity.
    Eur J Gastroenterol Hepatol. 2018 Feb 12. doi: 10.1097/MEG.0000000000001076.
    PubMed     Abstract available


  75. AKAR M, Aydin F, Yurci MA, Abay S, et al
    The possible relationship between Campylobacter spp./Arcobacter spp. and patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2018 Feb 9. doi: 10.1097/MEG.0000000000001095.
    PubMed     Abstract available


  76. NULSEN B, Sands BE, Shah BJ, Ungaro RC, et al
    Practices, attitudes, and knowledge about Crohn's disease and smoking cessation among gastroenterologists.
    Eur J Gastroenterol Hepatol. 2018;30:155-160.
    PubMed     Abstract available


  77. BROEKMAN MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, et al
    Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2018;30:167-173.
    PubMed     Abstract available


    January 2018
  78. GODAT S, Fournier N, Safroneeva E, Juillerat P, et al
    Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.
    Eur J Gastroenterol Hepatol. 2018 Jan 30. doi: 10.1097/MEG.0000000000001078.
    PubMed     Abstract available


  79. HERZOG D, Fournier N, Buehr P, Rueger V, et al
    Age at disease onset of inflammatory bowel disease is associated with later extraintestinal manifestations and complications.
    Eur J Gastroenterol Hepatol. 2018 Jan 22. doi: 10.1097/MEG.0000000000001072.
    PubMed     Abstract available


  80. ALLOCCA M, Gilardi D, Fiorino G, Furfaro F, et al
    Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men.
    Eur J Gastroenterol Hepatol. 2018 Jan 18. doi: 10.1097/MEG.0000000000001074.
    PubMed     Abstract available


  81. VAN ERP SJH, van der Have M, Fidder HH, van der Heijde D, et al
    The effect of arthropathies on illness perceptions, coping strategies, outcomes, and their changes over time in patients with inflammatory bowel disease: a 12-month follow-up study.
    Eur J Gastroenterol Hepatol. 2018 Jan 12. doi: 10.1097/MEG.0000000000001066.
    PubMed     Abstract available


  82. BLACKETT JW, Shamsunder M, Reilly NR, Green PHR, et al
    Characteristics and comorbidities of inpatients without celiac disease on a gluten-free diet.
    Eur J Gastroenterol Hepatol. 2018 Jan 8. doi: 10.1097/MEG.0000000000001071.
    PubMed     Abstract available


  83. KRAJCOVICOVA A, Kuzma M, Hlavaty T, Hans D, et al
    Decrease of trabecular bone score reflects severity of Crohn's disease: results of a case-control study.
    Eur J Gastroenterol Hepatol. 2018;30:101-106.
    PubMed     Abstract available


    December 2017
  84. WALLDORF J, Brunne S, Gittinger FS, Michl P, et al
    Family planning in inflammatory bowel disease: childlessness and disease-related concerns among female patients.
    Eur J Gastroenterol Hepatol. 2017 Dec 5. doi: 10.1097/MEG.0000000000001037.
    PubMed     Abstract available


    November 2017
  85. HOLKO P, Kawalec P, Mossakowska M
    Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study.
    Eur J Gastroenterol Hepatol. 2017 Nov 29. doi: 10.1097/MEG.0000000000001031.
    PubMed     Abstract available


  86. WILLEMZE RA, Bakker T, Pippias M, Ponsioen CY, et al
    beta-Blocker use is associated with a higher relapse risk of inflammatory bowel disease: a Dutch retrospective case-control study.
    Eur J Gastroenterol Hepatol. 2017 Nov 3. doi: 10.1097/MEG.0000000000001016.
    PubMed     Abstract available


    October 2017
  87. SKUJA V, Derovs A, Pekarska K, Rudzite D, et al
    Gut colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae may increase disease activity in biologic-naive outpatients with ulcerative colitis: an interim analysis.
    Eur J Gastroenterol Hepatol. 2017 Oct 25. doi: 10.1097/MEG.0000000000000989.
    PubMed     Abstract available


    September 2017
  88. BATTAT R, Kopylov U, Byer J, Sewitch MJ, et al
    Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study.
    Eur J Gastroenterol Hepatol. 2017 Sep 25. doi: 10.1097/MEG.0000000000000970.
    PubMed     Abstract available


  89. ARGUELLES-ARIAS F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, et al
    Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
    Eur J Gastroenterol Hepatol. 2017 Sep 8. doi: 10.1097/MEG.0000000000000953.
    PubMed     Abstract available


  90. TIMMER A, Stark R, Peplies J, Classen M, et al
    Current health status and medical therapy of patients with pediatric-onset inflammatory bowel disease: a survey-based analysis on 1280 patients aged 10-25 years focusing on differences by age of onset.
    Eur J Gastroenterol Hepatol. 2017 Sep 4. doi: 10.1097/MEG.0000000000000956.
    PubMed     Abstract available


    August 2017
  91. COUCOUTSI C, Emmanouil G, Goulielmos G, Sfakianaki O, et al
    Prevalence of thiopurine S-methyltransferase gene polymorphisms in patients with inflammatory bowel disease from the island of Crete, Greece.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000947.
    PubMed     Abstract available


    June 2017
  92. HOEKMAN DR, Zeevenhooven J, D'Haens GR, Benninga MA, et al
    The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Eur J Gastroenterol Hepatol. 2017 Jun 21. doi: 10.1097/MEG.0000000000000921.
    PubMed     Abstract available


  93. CARDILE S, Candusso M, Papadatou B, Bracci F, et al
    Lack of efficacy of infliximab in the treatment of primary sclerosing cholangitis in inflammatory bowel diseases in childhood.
    Eur J Gastroenterol Hepatol. 2017;29:736.
    PubMed    


    May 2017
  94. ORTIZO R, Lee SY, Nguyen ET, Jamal MM, et al
    Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies.
    Eur J Gastroenterol Hepatol. 2017 May 24. doi: 10.1097/MEG.0000000000000915.
    PubMed     Abstract available


  95. RINAWI F, Assa A, Eliakim R, Mozer Glassberg Y, et al
    Predictors of pouchitis after ileal pouch-anal anastomosis in pediatric-onset ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2017 May 24. doi: 10.1097/MEG.0000000000000914.
    PubMed     Abstract available


  96. BAHLER C, Schoepfer AM, Vavricka SR, Brungger B, et al
    Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000891.
    PubMed     Abstract available


  97. WARDLE RA, Wardle AJ, Charadva C, Ghosh S, et al
    Literature review: impacts of socioeconomic status on the risk of inflammatory bowel disease and its outcomes.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000899.
    PubMed     Abstract available


  98. HERZOG D, Fournier N, Buehr P, Rueger V, et al
    Prevalence of intestinal complications in inflammatory bowel disease: a comparison between paediatric-onset and adult-onset patients.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000896.
    PubMed     Abstract available


  99. SLONIM-NEVO V, Sarid O, Friger M, Schwartz D, et al
    Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2017;29:577-586.
    PubMed     Abstract available


  100. CHEN D, Luo S, Ben Q, Lu L, et al
    Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
    Eur J Gastroenterol Hepatol. 2017;29:509-515.
    PubMed     Abstract available


  101. GOTTGENS KW, Jeuring SF, Sturkenboom R, Romberg-Camps MJ, et al
    Time trends in the epidemiology and outcome of perianal fistulizing Crohn's disease in a population-based cohort.
    Eur J Gastroenterol Hepatol. 2017;29:595-601.
    PubMed     Abstract available


  102. WICKBOM A, Nyhlin N, Montgomery SM, Bohr J, et al
    Family history, comorbidity, smoking and other risk factors in microscopic colitis: a case-control study.
    Eur J Gastroenterol Hepatol. 2017;29:587-594.
    PubMed     Abstract available


    April 2017
  103. DRAGASEVIC S, Stankovic B, Milosavljevic T, Sokic-Milutinovic A, et al
    Genetic and environmental factors significant for the presentation and development of inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2017 Apr 27. doi: 10.1097/MEG.0000000000000877.
    PubMed     Abstract available


    March 2017
  104. VAN DEEN WK, Spiro A, Burak Ozbay A, Skup M, et al
    The impact of value-based healthcare for inflammatory bowel diseases on healthcare utilization: a pilot study.
    Eur J Gastroenterol Hepatol. 2017;29:331-337.
    PubMed     Abstract available


    February 2017
  105. YERUSHALMY-FELER A, Ron Y, Barnea E, Nachum A, et al
    Adolescent transition clinic in inflammatory bowel disease: quantitative assessment of self-efficacy skills.
    Eur J Gastroenterol Hepatol. 2017 Feb 22. doi: 10.1097/MEG.0000000000000864.
    PubMed     Abstract available


  106. TRIANTAFYLLOU K, Gkolfakis P, Viazis N, Tsibouris P, et al
    A 13-year time trend analysis of 3724 small bowel video capsule endoscopies and a forecast model during the financial crisis in Greece.
    Eur J Gastroenterol Hepatol. 2017;29:185-191.
    PubMed     Abstract available


  107. DURICOVA D, Fumery M, Annese V, Lakatos PL, et al
    The natural history of Crohn's disease in children: a review of population-based studies.
    Eur J Gastroenterol Hepatol. 2017;29:125-134.
    PubMed     Abstract available


    January 2017
  108. CHEN D, Luo S, Ben Q, Lu L, et al
    Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
    Eur J Gastroenterol Hepatol. 2017 Jan 21. doi: 10.1097/MEG.0000000000000838.
    PubMed     Abstract available


  109. COENEN S, Weyts E, Vermeire S, Ferrante M, et al
    Effects of introduction of an inflammatory bowel disease nurse position on the quality of delivered care.
    Eur J Gastroenterol Hepatol. 2017 Jan 21. doi: 10.1097/MEG.0000000000000839.
    PubMed     Abstract available


  110. SLONIM-NEVO V, Sarid O, Friger M, Schwartz D, et al
    Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2017 Jan 4. doi: 10.1097/MEG.0000000000000826.
    PubMed     Abstract available


    December 2016
  111. VAN ERP SJ, Verheul MK, Levarht EW, van der Reijden JJ, et al
    Absence of serological rheumatoid arthritis biomarkers in inflammatory bowel disease patients with arthropathies.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


  112. ROSSI RE, Whyand T, Murray CD, Hamilton MI, et al
    The role of dietary supplements in inflammatory bowel disease: a systematic review.
    Eur J Gastroenterol Hepatol. 2016;28:1357-1364.
    PubMed     Abstract available


    November 2016
  113. VAN GENNEP S, Sahami S, Buskens CJ, van den Brink GR, et al
    Comparison of health-related quality of life and disability in ulcerative colitis patients following restorative proctocolectomy with ileal pouch-anal anastomosis versus anti-tumor necrosis factor therapy.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


  114. ZEITZ J, Bissig M, Barthel C, Biedermann L, et al
    Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease?
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


  115. FALT P, Smajstrla V, Fojtik P, Hill M, et al
    Carbon dioxide insufflation during colonoscopy in inflammatory bowel disease patients: a double-blind, randomized, single-center trial.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


    October 2016
  116. GOYAL H, Singla U, Gupta U, May E, et al
    Role of cannabis in digestive disorders.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


  117. TAKS M, Pijls PA, Derijks LJ, Ten Broeke R, et al
    The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


  118. JOHNSEN KM, Goll R, Hansen V, Olsen T, et al
    Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


    September 2016
  119. FRAGA M, Fournier N, Safroneeva E, Pittet V, et al
    Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


    April 2016
  120. LEE YJ, Hwang EH, Park JH, Shin JH, et al
    NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2016;28:475-8.
    PubMed     Abstract available


    March 2016
  121. MADIRRALA V, Rooney P, Heath RM, Campbell F, et al
    Short article: Successful faecal coliform sensitivity-based oral ertapenem therapy for chronic antibiotic-refractory pouchitis: a case series.
    Eur J Gastroenterol Hepatol. 2016;28:277-80.
    PubMed     Abstract available


  122. BOND A, Asher R, Jackson R, Sager K, et al
    Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
    Eur J Gastroenterol Hepatol. 2016;28:271-6.
    PubMed     Abstract available


    February 2016
  123. KUIN S, Stolte SB, van den Brink GR, Ponsioen CY, et al
    Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2016;28:222-5.
    PubMed     Abstract available


    January 2016
  124. WAHID AM, Devarajan K, Ross A, Zilbauer M, et al
    Paediatric gastrointestinal endoscopy: a qualitative study.
    Eur J Gastroenterol Hepatol. 2016;28:25-9.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: